TMEM40 and melanoma: In the present study, RAF1 fusions involving the intact and in-frame RAF1 kinase domain were observed in 0.3% of all samples analyzed, and we observed 10 cases of RAF1 fusion, and these were composed of all different fusion partners: KRT8, TMEM40, LSAMP, and TAMM41 in gastric cancer; VPRBP in gallbladder cancer; TDRD10, IL6R, SHE, and SLC25A20 in melanoma; CACNA2D3 and PFKFB4 in pancreatic cancer; and APPL2 in sarcoma.